MA-EUSA-PHARMA
17.12.2020 09:02:18 CET | Business Wire | Press release
EUSA Pharma (UK) Limited (“EUSA Pharma ”), a global biopharmaceutical company, announced today that the first patient has been enrolled in the SIL tuximab in V iral AR DS (‘SILVAR ’) study at the Sparrow Hospital in Lansing, Michigan. The ‘SILVAR’ study is a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel-arm, Phase 3 study designed to confirm the encouraging results of the observational, single-centre, control-cohort in the Si ltuximab In S erious CO VID-19 (‘SISCO ’) study.1 The results from 30 patients treated with siltuximab in the ‘SISCO’ study compared with 30 matched controls, showed that treatment with siltuximab led to a 54% reduction in risk of 30-day all-cause mortality.2
This pivotal study will evaluate the efficacy and safety of standard of care (SOC) with or without intravenous siltuximab in selected hospitalised patients with COVID-19 previously treated with corticosteroids or another respiratory virus infection. Unlike previous studies of agents targeting the interleukin-6 (IL-6) signalling pathway, the ‘SILVAR’ study has been rationally designed to only enrol those hospitalised patients suffering from serious viral acute respiratory distress syndrome (ARDS) in a hyperinflammatory state that will most likely benefit from the addition of an anti-IL-6 immunomodulator such as siltuximab.
Lee Morley, Chief Executive Officer, EUSA Pharma, said, “We are delighted to have enrolled the first patient in the ‘SILVAR’ study of siltuximab, a monoclonal antibody that binds to and neutralises IL-6, an important mediator of the immune response to infection. This clinical trial represents an important step in finding a solution for hospitalised patients with serious respiratory complications due to an over reactive immune response to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection that is not fully responsive to corticosteroid therapy, as well as those with any other respiratory virus infection associated with serious ARDS.”
Zainab Shahid, MD, FACP, infectious disease physician with Atrium Health and Lead Principal Investigator on the ‘SILVAR’ study, said, “Patients with serious viral ARDS have some of the highest mortality rates despite recent improvements in intensive care. The ‘SILVAR’ study is a very important step to potentially confirm the encouraging results of the Italian observational cohort-control ‘SISCO’ study in a prospective, randomised, controlled fashion.”
References
1. Siltuximab In Serious COVID-19 (SISCO) study (NCT04322188); https://www.clinicaltrials.gov/ct2/show/NCT04322188
2. Gritti G, et al. IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study. medRxiv June 2020; DOI: https://doi.org/10.1101/2020.04.01.20048561
.
-----
About the ‘SILVAR’ Study
SIL
tuximab in V
iral AR
DS (‘SILVAR
’) is an FDA-approved, prospective, multicentre, randomised, double-blind, placebo-controlled, parallel-arm, Phase 3 clinical trial designed to compare the efficacy and safety of intravenous siltuximab plus SOC to intravenous normal saline plus SOC in selected hospitalised patients with COVID-19 previously treated with corticosteroids or another respiratory virus infection associated with ARDS. This US multicentre clinical trial will aim to enrol approximately 555 patients with serious viral ARDS and elevated serum levels of IL-6 as measured by its qualified C-reactive protein (CRP) surrogate. The primary objective is to demonstrate a significant reduction in 28-day mortality with the addition of siltuximab to SOC. Secondary objectives are to compare other measures of efficacy between both treatment arms and to evaluate the safety, tolerability, exposure, and immunogenicity of siltuximab in this patient population and treatment setting. For more information, please visit www.clinicaltrials.gov/ct2/show/NCT04616586
.
About Siltuximab
Siltuximab is a monoclonal antibody that directly neutralises IL-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions. It is currently approved by the US Food and Drug Administration (FDA) and the European Commission (EC), as well as health regulatory authorities in several other jurisdictions worldwide, for the treatment of adult patients with Multicentric Castleman Disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. EUSA Pharma has exclusive rights to siltuximab (SYLVANT®
▼) globally. Indications and Usage of SYLVANT
– See EMA Summary of Product Characteristics (SmPC)
and FDA Prescribing Information
for additional information.
About EUSA Pharma
Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease. The company is headquartered in Hemel Hempstead, England (UK), and has extensive commercial operations in the United States and Europe, alongside a direct presence in selected other markets across the globe. EUSA Pharma is led by an experienced management team with a strong record of building successful pharmaceutical companies, and it is supported by significant funding raised from leading life science investor EW Healthcare Partners. For more information, please visit www.eusapharma.com
.
About Atrium Health
Atrium Health
is a nationally recognized leader in shaping health outcomes through innovative research, education and compassionate patient care. Atrium Health is an integrated, non-profit health system with more than 70,000 teammates serving patients at 42 hospitals and more than 1,500 care locations. It provides care under the Wake Forest Baptist Health
name in the Winston-Salem, North Carolina, region and Navicent Health
in Georgia. Atrium Health is renowned for its top-ranked pediatric, cancer and heart care, as well as organ transplants, burn treatments and specialized musculoskeletal programs. A recognized leader in experiential medical education and ground breaking research, Wake Forest School of Medicine
is the academic core of the enterprise, including Wake Forest Innovations
, which is advancing new medical technologies and biomedical discoveries. Atrium Health is also a leading-edge innovator in virtual care and mobile medicine, providing care close to home and in the home. Ranked among U.S. News & World Report
’s Best Hospitals for cancer treatment and in eight pediatric specialties, Atrium Health has also received the American Hospital Association’s Quest for Quality Prize and was the recipient of the 2020 Centers for Medicare & Medicaid Services Health Equity Award for its efforts to reduce racial and ethnic disparities in care. With a commitment to every community it serves, Atrium Health seeks to improve health, elevate hope and advance healing – for all, providing more than $2 billion per year in free and uncompensated care and other community benefits.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005180/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Klarna Reports Third Quarter 2026 Results17.11.2026 13:45:00 CET | Press release
Klarna Group plc (NYSE: KLAR), the everyday finance network, today reported third quarter 2026 results. GMV reached $36.1 billion (+10% YoY), revenue $1.0 billion (+12% YoY), transaction margin dollars (TMD) $371 million (+32% YoY), and adjusted operating income $21 million (+$35m YoY). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116206092/en/ "Q3 was our fourth straight quarter with revenue above 1 billion dollars and positive adjusted operating income. We are keeping more of each dollar we process through our everyday finance network: transaction margin is now 37% of revenue, up from 31% a year ago. Looking ahead, we’re finishing the year strong as we are running on track with, or ahead of, all our full year outlook.” Sebastian Siemiatkowski, CEO & Co-Founder, Klarna Klarna’s full earnings release is available at the Quarterly Results section of its website at https://investors.klarna.com/financials/quarterly-results
Would You Let AI Manage Your Next Trip?17.11.2026 13:06:00 CET | Press release
New research suggests AI agents could change how travelers choose airlines and hotels by 2032The Intelligent Journey 2032 explores four directions travel could take by early in the next decade, and how technology, particularly AI, will connect travelers with airlines, airports, hotels and other travel companies.The study suggests the future will be defined by travelers deciding what they are willing to delegate, with clear consent, spending limits, and the ability to retain control as key considerations.It also identifies travel orchestration as the strategic prize for the industry, as AI could reshape travel commerce, and shift value toward those able to coordinate the entire journey across suppliers, payments, identity, disruption and service. AI is already transforming the traveler journey, helping people discover, plan and navigate their trips. The question is how far travelers will let AI make decisions for them in the future: booking, paying, changing plans and recovering from di
Iconic Raises $10M to Build Software That Understands the World’s Biggest Projects17.11.2026 13:01:00 CET | Press release
Iconic has raised $10 million in seed funding led by Peak Capital, with participation from Bridford Group, Common Magic, Graduate Ventures, NP-Hard, and Tiny VC. Since its founding in mid-2025, Iconic has signed five clients in energy, infrastructure, and AI infrastructure: a global energy major, a leading European utility, a major European airport, a European rail infrastructure owner, and a global contractor building semiconductor fabs and data centers. Each spends over $1 billion annually on capital projects. An estimated $15 trillion is invested in capital projects annually, yet fewer than 3% are delivered on time, on budget, and to plan. Capital projects rarely fail because of engineering complexity, but because decisions are made without a complete understanding of the project. Information is fragmented across documents and systems shared by owners, contractors, and engineering firms. Decisions are hard to reverse, with consequences lasting years through delays, claims, and cost
Quaise Energy Signs 50 MW Geothermal Power Purchase Agreement with Google17.11.2026 12:50:00 CET | Press release
Agreement advances development of commercial-scale superhot geothermal, will supply carbon-free energy to Oregon communities as early as 2030 Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that Google has signed a power purchase agreement (PPA) for 50 megawatts (MW) of superhot geothermal power from Project Obsidian, Quaise’s flagship project in Central Oregon. Once online, this always-on, carbon-free energy is slated to support Google’s existing data center operations in The Dalles, Ore. and the region’s communities. The agreement will help catalyze the commercial development of superhot geothermal energy, providing benefits for ratepayers and helping protect the environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117923219/en/ Beginning as early as 2030, Google will purchase 50 MW of power from Project Obsidian. The initial phase of development will use convention
Nowhere to Sit, Nothing to Do: Europe’s Biggest Airports Fall Short for Passengers17.11.2026 12:24:00 CET | Press release
AirHelp data shows that nearly half of Europe’s biggest airports score below the global average for both seating and entertainment. One in four of Europe’s 50 biggest airports scores below the global average on all four parts of the experience passengers rated, according to AirHelp data covering 279 airports worldwide. Passengers rated each airport on wait times, restaurants, seating and entertainment. Twelve airports, including Dublin, Manchester, Lisbon, London Luton and Milan Bergamo, came in below the global average on all four. Only four beat all four averages: Zurich, Warsaw, Naples and Ankara. Entertainment is the weak spot almost everywhere Entertainment was the lowest-rated part of the experience at 45 of the 50 airports, averaging 6.5 out of 10, with more than half of the airports falling below the global average of 6.7. Seven airports scored less than 6, including Manchester, Stansted, Dublin and Oslo. The data also suggests that passengers who can’t find a seat usually have
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
